
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2018

Commission File Number: 001-38067

Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)

3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 3, 2018, Verona Pharma plc (the “Company”) announced the outcome of resolutions proposed at the Annual General Meeting.

The press release is furnished herewith as Exhibits 1, to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
1	Result of AGM

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: May 4, 2018

By: /s/ Jan-Anders Karlsson

Name: Jan-Anders Karlsson, Ph.D.

Title: Chief Executive Officer



Verona Pharma

Result of AGM

03 May 2018, London– Verona Pharma plc (AIM: VRPL), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General Meeting (AGM) held yesterday were duly passed.

- End -

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)

Tel: +44 (0) 20 7710 7600

Stewart Wallace / Jonathan Senior / Ben Maddison

SNELVeronaPharma@stifel.com

FTI Consulting (UK Media and Investor enquiries)
Simon Conway / Natalie Garland-Collins

Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins

Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington

Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com